Journal of Jishou University(Natural Sciences Edition) ›› 2022, Vol. 43 ›› Issue (6): 67-74.DOI: 10.13438/j.cnki.jdzk.2022.06.012

• Medical • Previous Articles     Next Articles

Effect of Nimotuzumab Combined with GP Chemotherapy in the Treatment of Metastatic Nasopharyngeal Carcinoma

CHEN Jia,XIANG Zhibi,XIONG Li,DUAN Hexin,LIU Rong,YANG Zhi,WU Hui,YANG Zaichuan   

  1. (Department of Oncology,Xiangxi Autonomous Prefecture People's Hospital,the First Affiliated Hospital of Jishou University,Jishou 416000,Hunan China)
  • Online:2022-11-25 Published:2023-01-10

Abstract: The efficacy and adverse reactions of nituzumab combined with GP chemotherapy in the treatment of metastatic nasopharyngeal carcinoma has been analyzed.Patients diagnosed by the pathology and the imaging of advanced metastatic nasopharyngeal carcinoma from June 1,2019 to December 31,2020 in Xiangxi Autonomous Prefecture People's Hospital,and were randomly divided into experimental group (GP + Nimotuzumab)and control group (GP) .The effective rate,disease control rate,progression-free survival,overall survival and adverse reactions of the two groups were compared and analyzed.A total of 28 patients were included in this study,including 14 in the experimental group and 14 in the control group.In the experimental group there were 1 case of CR,10 cases of PR,2 cases of SD,and 1 case of PD;and in the control group,ORR of the experimental group and control group was 78.5% vs 50.0%(P=0.115),and DCR 92.8% vs 85.7%(P=0.541).The median DOR was 7 months in the experimental group and 5 in the control group (P=0.068).The median PFS of the experimental group and the control group were 11 months and 7 months (P=0.043).The median OS was 19 months in experimental group and 13 months in control group (P=0.043) .The main adverse reactions in both groups were myelosuppression,gastrointestinal reactions and hepatic injury.Degrees of myelosuppression occurred in 11 patients in the experimental group and in 12 in the control group (P=0.662).The rates of grade 1~2 myelosuppression in the two groups were 50.00% vs 25.00% (P=0.115),while 3~4 grade in the two groups were (33.33% vs 64.28%,P=0.058).Grade 1~2 gastrointestinal reactions occurred in both groups 35.71% vs 50.00% (P=0.445).The incidence of grade 1~2 hepatic injury was (21.43% vs 7.14%,P=0.280),and that of grade 3~4 hepatic injury was the same (7.14%) .Compared with GP alone,GP +Nimotuzumab did not improve the short-term efficacy in the treatment of advanced metastatic nasopharyngeal carcinoma,but prolonged the PFS time,improved the overall survival,and did not increase the adverse reactions.

Key words: metastatic nasopharyngeal carcinoma, nimotuzumab, GP treatment, effect

WeChat e-book chaoxing Mobile QQ